As the pharmaceutical industry constantly strives to bring new, effective drugs to market, the discovery of small molecule leads has become a crucial step in the drug development process. That’s where Nuevolution comes in – a leading small molecule lead discovery company based in Copenhagen, Denmark. In this startup showcase, we explore how Nuevolution is revolutionizing drug discovery through its unique technology, Chemetics®, and its partnerships with some of the biggest names in the pharmaceutical and biotechnology industries.
Introducing Nuevolution
Founded in 2001, Nuevolution has established itself as a pioneer in the field of small molecule lead discovery. The company’s patented technology, Chemetics®, combines the best of both worlds – wet chemistry and molecular biology – to enable the rapid synthesis and screening of hundreds of millions of drug-like small molecule compounds. Chemetics® has already proven to be a game-changer in the drug discovery landscape, allowing Nuevolution to identify highly potent and drug-like novel ligands with the potential to address major unmet medical needs across a range of therapeutic areas and target classes.
Partnerships with Industry Giants
Nuevolution’s unique technology has not gone unnoticed by the pharmaceutical and biotechnology industries. The company has entered into agreements with some of the biggest names in the field, including Merck & Co., Lexicon Pharmaceuticals, GlaxoSmithKline, Novartis Pharma, and Boehringer Ingelheim. Through these partnerships, Nuevolution is able to apply its technology to partner-funded programs and collaborative projects, bringing its expertise in small molecule lead discovery to a wider audience.
Joint Venture Consortium for Epigenetic Drug Discovery
Nuevolution is also part of a joint venture consortium with EpiTherapeutics, ExpreS2ion Biotechnologies, and Professor Kristian Helin of the Biotech Research & Innovation Centre at the University of Copenhagen. This project, which is supported by the Danish High Technology Fund with a $4 million budget, aims to discover and develop novel small molecule drugs against epigenetic factors. Nuevolution’s Chemetics® technology is expected to play a key role in this endeavor, demonstrating once again its power in the discovery of small molecule leads.
Despite its success, Nuevolution remains a privately owned company by key Scandinavian investors, including Industrifonden, SEB Venture Capital, Sunstone Capital, SLS Invest, and Novo A/S. This ownership structure allows the company to maintain its independence and focus on its mission of revolutionizing small molecule lead discovery.
Conclusion
In conclusion, Nuevolution’s unique technology, Chemetics®, has already demonstrated its power in the discovery of small molecule leads, and the company’s partnerships with industry giants and joint venture consortium for epigenetic drug discovery are a testament to its potential. As the pharmaceutical industry continues to evolve, Nuevolution is well-positioned to remain at the forefront of small molecule lead discovery.
Website: http://www.nuevolution.com/
Facebook: https://www.facebook.com/nuevolutionab
LinkedIn: http://www.linkedin.com/company/nuevolution
Want to amplify your startup’s story? EU Startup News is your launchpad to reach startup founders, investors, and C-level execs across Europe. Discover our tailored promotional strategies such as Sponsored Articles and Partnerships. Click here to learn more or contact us directly at [email protected]. Join us, and let’s make your startup the talk of Europe!
